These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31152369)

  • 1. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
    Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
    Sánchez P; Meca-Lallana V; Vivancos J
    Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
    Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
    Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with fingolimod rebound: A single center real-life experience.
    Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
    Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
    Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
    Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
    Harirchian MH; Taalimi A; Siroos B
    Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
    Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
    CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebound activity after fingolimod cessation: A case - control study.
    Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
    Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection.
    Giovannini B; Panelli D; Bianchi F; Siciliano G; Pasquali L
    Neurol Sci; 2024 Jun; 45(6):2423-2426. PubMed ID: 38546935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
    Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U
    Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different MRI patterns in MS worsening after stopping fingolimod.
    Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
    Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.